I reiterate a 'Buy' rating on the Global X Robotics & Artificial Intelligence ETF, anticipating a major trigger from potential U.S. government support. BOTZ offers concentrated exposure to robotics and AI, with Nvidia as its top holding and nearly 60% in its top ten positions. Three core arguments support the fund: imminent policy catalysts, sector deleveraging with improving fundamentals, and attractive valuation at 36x P/E vs. a 50x historical high.
Reiterate buy recommendation on Global X Robotics & Artificial Intelligence ETF, emphasizing untapped upside despite recent gains. BOTZ stands out for AI and robotics exposure, robust holdings like NVDA, ABBNY, and FANUY, and a $3.1B AUM with a 0.68% expense ratio. Arguments against an AI bubble include stronger accounting standards, fewer unprofitable tech firms, and strategic deglobalization driving real AI demand.
I recommend buying the Global X Robotics & Artificial Intelligence ETF for exposure to exponential AI and robotics growth across diverse sectors, supported by Morgan Stanley's expanded 'Humanoid 100' list. BOTZ offers diversified holdings beyond pure tech, including automation, healthcare, and industrial applications, with attractive valuation and positive momentum. Rapid adoption of AI models and applications, plus historic productivity gains, suggest robotics and humanoid robots will see similar exponential uptake.
BOTZ offers broad exposure to robotics and AI. The ETF leans heavily toward industrials and intentional companies, with low semiconductor exposure. It's a refreshing change. However, performance lags peer AI/robotics ETFs.
Maybe it's just my perception, but it feels as if innovation is truly accelerating. In just the last two years, we've experienced the integration of seemingly magical artificial intelligence into everyday life, major breakthroughs in quantum computing, and now, the emergence of humanoid robotics on the commercial stage.
BOTZ caught my attention after the P/E contraction from 37x to 29x in just a few months. It has a strong concentration in Japan (over 30%), which I consider a positive factor from a forward-looking perspective. It focuses on automation, so although its name includes AI and robotics, it is not 100% tech but has a well-diversified industry breakdown.
AI technologies are transitioning from a fad to a cornerstone of the new economy. AI's integration into various sectors is becoming a reality, evidenced by growth projections in data center. BOTZ is diversified across Capital Goods, hardware, and healthcare, reducing valuation premiums due to lower concentration in software and semiconductors. With a fair valuation, the market may be underestimating the time in which technological innovations in robotics can be implemented.
The Information Technology sector, led by AI-related stocks like NVIDIA, has shown recent gains, but BOTZ ETF remains underperforming with valuation concerns. BOTZ ETF, focusing on robotics and AI, has a high P/E ratio and mixed technicals, with a bullish seasonal trend from mid-October to January. Despite a solid long-term EPS growth rate of 12.6%, BOTZ's concentrated allocation and high standard deviation history make it a risky investment.
After a brief lull, the fervor for artificial intelligence (AI) investments is back with a bang on Wall Street.
After a brief lull, the fervor for artificial intelligence (AI) investments is back with a bang on Wall Street.
BOTZ is a global ETF focused on robotics and AI, with top holdings including Nvidia, ABB Ltd, and Intuitive Surgical Inc. The robotics and AI industry is rapidly evolving, with applications in manufacturing, logistics, healthcare, and cybersecurity. While the potential for growth in the industry is high, investors should exercise caution and consider the long-term prospects of ETFs like BOTZ.
The pandemic was a wake-up call for many companies, highlighting the fragility of their supply chains. After the pandemic, nearshoring, or the act of moving business production closer to home to neighboring countries, has become an important disruptive theme.